+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pneumococcal Vaccines Market and Forecast Analysis to 2022

  • ID: 3797451
  • Drug Pipelines
  • 145 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Streptococcus Pneumoniae is a major cause of morbidity and mortality worldwide, with an estimated 1.6 million people dying of invasive pneumococcal disease (IPD) each year. IPD primarily comprises septicemia, pneumonia, and meningitis. However, S. Pneumoniae infections can also lead to other diseases such as bronchitis or pericarditis. IPD occurs most commonly among the very young (24 months) and the elderly (65 years); the elderly have the highest IPD mortality rates.

Market Snapshot
  • Market growth will be maintained by price rises, increased vaccination uptake in the elderly, and a stable infant population.
  • Prevnar 13 will continue to dominate US and EU markets, but pipeline vaccines could pose formidable threats from 2022.
  • V114 and GSK-3 will threaten the dominance of Prevnar 13 with potential for broader coverage, starting in 2022.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)
Overview
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Us Market Forecast
Japan Market Forecast
France Market Forecast
Germany Market Forecast
Italy Market Forecast
Spain Market Forecast
Uk Market Forecast
Product Profile: Prevnar
Product Profile (Late Stage): V114

MARKETED DRUGS: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)
Overview
Product Overview
Product Profile: Pneumovax
Product Profile: Prevnar
Product Profile: Synflorix

PIPELINE: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)
Overview
Clinical Pipeline Overview
Product Profile (Late Stage): Gsk-3
Product Profile (Late Stage): Pf-06482077
Product Profile (Late Stage): V114

LIST OF FIGURES
Figure 1: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by risk group, 2017-26
Figure 3: Total sales of pneumococcal vaccines in the US, by risk group, 2017-26
Figure 4: Total sales of pneumococcal vaccines in the five major EU markets, by brand, 2017-26
Figure 5: Total sales of pneumococcal vaccines in Japan, by brand, 2017-26
Figure 6: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by brand, 2017-26
Figure 7: Patient-based forecasting methodology for pneumococcal vaccines
Figure 8: Price sources and calculations, by country
Figure 9: Total sales of pneumococcal vaccines in the US, by brand, 2017-26
Figure 10: Total sales of pneumococcal vaccines in the US, by risk group, 2017-26
Figure 11: Pneumococcal vaccination coverage in the US, by risk group, 2017-26
Figure 12: Total sales of pneumococcal vaccines in Japan, by brand, 2017-26
Figure 13: Total sales of pneumococcal vaccines in Japan, by risk group, 2017-26
Figure 14: Pneumococcal vaccination coverage in Japan, by risk group, 2017–26
Figure 15: Total sales of pneumococcal vaccines in France, by risk group, 2017-26
Figure 16: Total sales of pneumococcal vaccines in France, by brand, 2017-26
Figure 17: Pneumococcal vaccination coverage in France, by risk group, 2017–26
Figure 18: Total sales of pneumococcal vaccines in Germany, by brand, 2017-26
Figure 19: Total sales of pneumococcal vaccines in Germany, by risk group, 2017-26
Figure 20: Pneumococcal vaccination coverage in Germany, by risk group, 2017-26
Figure 21: Total sales of pneumococcal vaccines in Italy, by brand, 2017-26
Figure 22: Total sales of pneumococcal vaccines in Italy, by risk group, 2017-26
Figure 23: Pneumococcal vaccination coverage in Italy, by risk group, 2017-26
Figure 24: Total sales of pneumococcal vaccines in Spain, by risk group, 2017-26
Figure 25: Total sales of pneumococcal vaccines in Spain, by brand, 2017-26
Figure 26: Pneumococcal vaccination coverage in Spain, by risk group, 2017–26
Figure 27: Total sales of pneumococcal vaccines in the UK, by brand, 2017-26
Figure 28: Pneumococcal vaccination coverage in the UK, by risk group, 2017–26
Figure 29: Pneumovax 23 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Prevnar 13 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26
Figure 31: V114 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Pneumovax 23 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26
Figure 33: Prevnar 13 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26
Figure 34: V114 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Recommendations for pneumococcal vaccination by national authorities, 2018
Table 2: Exchange rates used for calculating prices
Table 3: Pneumovax 23 drug profile
Table 4: Approval history of Pneumovax 23 for pneumococcal vaccination in the US, Japan, and five major EU markets
Table 5: Pneumococcal vaccine recommendations for Pneumovax 23, by country and age group
Table 6: Late-phase trials of Pneumovax 23 for pneumococcal vaccination
Table 7: Pneumovax 23 for pneumococcal vaccination – SWOT analysis
Table 8: Prevnar 13 drug profile
Table 9: Approval history of Prevnar 13 for pneumococcal vaccination in the US, Japan, and five major EU markets
Table 10: Pneumococcal vaccine recommendations for Prevnar 13, by country and age group
Table 11: Late-phase trials of Prevnar 13 for pneumococcal vaccination
Table 12: Prevnar 13 for pneumococcal vaccination – SWOT analysis
Table 13: V114 drug profile
Table 14: Trials of V114 for pneumococcal vaccination
Table 15: V114 for pneumococcal vaccination – SWOT analysis
Table 16: Profiled key marketed drugs for pneumococcal disease
Table 17: Pneumovax 23 drug profile
Table 18: Approval history of Pneumovax 23 for pneumococcal vaccination in the US, Japan, and five major EU markets
Table 19: Pneumococcal vaccine recommendations for Pneumovax 23, by country and age group
Table 20: Late-phase trials of Pneumovax 23 for pneumococcal vaccination
Table 21: Pneumovax 23 for pneumococcal vaccination – SWOT analysis
Table 22: Prevnar 13 drug profile
Table 23: Approval history of Prevnar 13 for pneumococcal vaccination in the US, Japan, and five major EU markets
Table 24: Pneumococcal vaccine recommendations for Prevnar 13, by country and age group
Table 25: Late-phase trials of Prevnar 13 for pneumococcal vaccination
Table 26: Prevnar 13 for pneumococcal vaccination – SWOT analysis
Table 27: Synflorix drug profile
Table 28: Approval history of Synflorix for pneumococcal vaccination in Japan and the five major EU markets
Table 29: Late-phase trials of Synflorix for pneumococcal vaccination
Table 30: Synflorix for pneumococcal vaccination – SWOT analysis
Table 31: Profiled key late-stage pipeline products for pneumococcal vaccination
Table 32: GSK-3 drug profile
Table 33: Trials of GSK-3 for pneumococcal vaccination
Table 34: GSK-3 for pneumococcal vaccination – SWOT analysis
Table 35: PF-06482077 drug profile
Table 36: Trials of PF-06482077 for pneumococcal vaccination
Table 37: PF-06482077 for pneumococcal vaccination – SWOT analysis
Table 38: V114 drug profile
Table 39: Trials of V114 for pneumococcal vaccination
Table 40: V114 for pneumococcal vaccination – SWOT analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll